Abstract
ObjectivesWe assessed the safety and effectiveness of direct-to-patient telehealth provision of medication abortion in Australia. Study designWe included all medication abortions (January 2017–December 2018) from Marie Stopes Australia's patient management and adverse event reporting systems. We defined effectiveness as whether the patient had a continuing pregnancy, incomplete abortion, and/or subsequent vacuum aspiration or procedural abortion and safety as whether the patient experienced any adverse event. ResultsDirect-to-patient telehealth was more effective than in-clinic provision (97.2% vs 95.4%). The proportion of adverse events did not differ between groups. ConclusionsThis direct-to-patient telehealth service is safe and effective.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have